期刊文献+

多表位恶性疟疾疫苗M.RCAg-1在大肠杆菌表达的条件优化和大规模培养 被引量:2

The optimal condition for expression and large-scale culture of candidate vaccine against Plasmodium falciparum in E. coli
下载PDF
导出
摘要 通过以培养基配方、IPTG浓度、金属离子复合液浓度、镁离子浓度、表达时间、接种量、诱导时间点等发酵的重要条件对重组蛋白表达量影响的研究,确定多表位恶性疟疾疫苗M.RCAg-1蛋白最佳表达条件为以改良TB培养基培养、最优Mg2+,诱导剂IPTG和金属离子复合液浓度分别为10mmol/L,0.5mmol/L,6μl/ml,接种量为10%,表达时间为4.5h,将优化后的参数用于50L发酵罐进行连续3批中试规模的发酵,最终收获菌体湿重平均为31.8±1.78g/L,目的蛋白表达量可占菌体总蛋白的50%左右,试验确定了恶性疟疾多表位随机组合蛋白M.RCAg-1在大肠杆菌中的最优表达条件,该条件能够适合大规模培养需要。 The factors influencing the expression of recombination protein and vaccine culture were detected these factors inelude the medium composition, concentration of IPTG, the concentration of metalions compound liquid, ionic strength of Mg^2+ , expression time, inoculum dose, induction time and induction dose. The results showed that the optimal conditions for the expression of recombination protein and vaccine culture are as follows : the modified TB culture medium is the best, the optimal concentration of Mg^2+ , inducer IPTG and ions compound liquid was 10mmol / L, 0.5mmol / L, 6μl/ml respectively, the inoculum dose is 10% and the induction time is 4.5 h. three consecutive bathes of fermentation culture in a polot scale were carried out at the conditions of the above mentioned optimal parameters. The yield of bacteria reaches the average value of 31.8 ± 1.78g/L and the expressing level of recombinant M. RCAg-1 is about 50% of the host protein in 50 liter fermentor. These conditions can be suitable for large scale culture.
出处 《微生物学免疫学进展》 2009年第3期29-33,共5页 Progress In Microbiology and Immunology
基金 国家863"疫苗与抗体工程"重大专项资助(No.2006AA02A224)
关键词 恶性疟疾 大肠杆菌 表达优化 Plasmodium falciparum Escherichia coli Optimized expression
  • 相关文献

参考文献9

  • 1SnowRW, Guerra CA, Noor AM,et al. The global distribution of clinical episodes of PIasmodium falciparum malaria [ J ]. Nature 2005,434 (7030) :214- 217.
  • 2J 萨姆布鲁克,D W 拉塞尔.分子克隆实验指南[M].第3版.北京:科学出版社,2002:304-340.
  • 3舒红,任常山.人神经生长因子的A-T克隆及在Pichia pastoris酵母中的表达(英文)[J].中国现代医学杂志,2004,14(11):21-25. 被引量:5
  • 4刘照惠,邵丽君,李猛,金立杰,李利,谷丽娟,赵晓琳,杨屹.HBV PreS2-MBP融合蛋白在大肠杆菌中表达条件的优化[J].中国生物制品学杂志,2007,20(6):435-438. 被引量:4
  • 5汪永信,钟辉,曹诚,张艳红,张部昌,马清钧.pcD-awte候选疟疾DNA疫苗发酵条件的探索[J].生物学杂志,2007,24(5):16-19. 被引量:1
  • 6Cai QL, Wei F, Lin YH, et al. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria [ J ]. Vaccine 2004,23(2) : 267- 277.
  • 7Cai QL, Peng G, Bu L, et al. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling [ J ]. Vaccine 2007,25 (28) : 5155- 5165.
  • 8Zhou Z, Todd CW, Wohlhueter RM, et al. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen ( FALVAC-1 A) expressed in Escherichia coli[J]. Hum Vaccin 2006,2(1 ) : 14- 23.
  • 9Dipti CA, Jain SK, Navin K. A novel recombinant multiepitope protein as a hepatitis C diagnostic intermediate of high sensitivity and specificity[J]. Protein Expr Purif 2006, 47(1) : 319- 328.

二级参考文献24

共引文献16

同被引文献13

  • 1Waters A. Malaria: new vaccines for old [J]. Cell, 2006, 124 (4): 689-693.
  • 2Greenwood BM, Targett GA. Malaria vaccines and the new malaria agenda [J].Clin Microbiol Infect, 2011,17 ( 11 ) : 1600-1607.
  • 3Cai QL, Wei F, Lin YH, et al. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria [J].Vaccine, 2004, 23 (2) : 267-277.
  • 4Li WL, Liu EX, Fan RG, et al. Characterization of plasmodium yoelii antigens by monoclonal antibodies, I , Common antigens between erythrocytic stages 9f plasmodium yoelii and human malaria parasites [J]. Ji Sheng Chong Xue /de Ji Sheng Chong Bing Za Zhi, 1984,2(2) : 83-87.
  • 5Yang T, Wang HN, Wang X, et al, Multivalent DNA vaccine enhanced protection efficacy against infectious bronchitis virus in chickens [J]. J Vet Med Sci, 2009, 71 (12): 1585-1590.
  • 6Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming "vaccine resistant malaria [J]. Parasite Immund, 2009, 31 (9): 560-573.
  • 7Mahanty S, Saul A, Miller LH. Progress in the development of recombinant and synthetic blood-stage malaria vaccines [J]. J Exp Biol, 2003, 206 (Pt 21) :3781-3788.
  • 8Olugbile S, Villard V, Bertholet S, et al. Malaria vaccine candidate: design of a multivalent subunit alpha-helical coiled coil poly-epitope [J]. Vaecine, 2011,29 (40): 7090-7099.
  • 9Zhou Z, Todd CW, Wohlhueter RM, et ol. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli[J]. Hum Vaccin, 2006, 2( 1 ) : 14-23.
  • 10Dipti CA, Jain SK, Navin K. A novel recombinant muhiepitope protein as a hepatitis C diagnostic intermediate of high sensitivity and specificity [J]. Protein Expr Purif, 2006, 47 (1): 319-328.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部